Spinal Muscular Atrophy Market - Size, Share, Trends, and Forecast, 2022 - 2028

Spinal Muscular Atrophy Market - Size, Share, Trends, and Forecast, 2022 - 2028

Spinal muscular atrophy (SMA) is a rare, genetically inherited neuromuscular condition. The disease causes loss of movement and progressive muscle weakness due to muscle wasting (atrophy). The disease is divided into four subtypes (1 to 4) on the basis of the age of onset. SMA type 1 (SMA1) is the most severe form and most common genetic cause of death among infants. Various drugs are available in the market to treat the symptoms of the diseases, however, only one drug is approved for the treatment of SMA so far. Muscle relaxants such as tizanidine, baclofen, and the benzodiazepines can reduce spasticity. Excessive saliva can be treated with glycopyolate, amitriptyline, and atropine or by botulinum injections into the salivary glands. Antidepressants can be helpful in treating depression. Botulinum toxin can also be used to treat drooling or jaw spasms.
Market Dynamics
Major factors driving growth of the spinal muscular atrophy market includes increasing number of clinical trials and rising government support for R&D. Biotechnology and biopharmaceutical companies are working towards development of effective therapies to treat spinal muscular atrophy. For instance, in 2016, the U.S. FDA approved Spinraza (nusinersen) drug from Biogen for the treatment of SMA. Spinraza targets the underlying defect in SMA, so it can help prevent, delay, or even reverse the symptoms.
However, its common side effects include higher risk of constipation and respiratory tract infection along with minimal risk of kidney problems and bleeding. Moreover, the cost of research for development of new therapy is also high. With the advancements of drug in the pipeline, its expense and time for development also increases. According to Cure SMA, it can take over 15 years and US$ 100 million for a single drug candidate to reach FDA approval. These factors make research challenging particularly for a disease such as SMA. These factors are expected to hinder growth of the market.
Key features of the study:

This report provides in-depth analysis of spinal muscular atrophy market and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by the leading players
It profiles leading players in the global spinal muscular atrophy market based on the following parameters – company overview, financial performance, product portfolio, market presence, key developments, strategies, and future plans
Key companies covered as a part of this study include Biogen, Cytokinetics, Inc., F. Hoffmann-La Roche, Novartis AG, Pfizer Inc., and Ionis Pharmaceuticals, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
The global spinal muscular atrophy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the spinal muscular atrophy market

Detailed Segmentation:

Global Spinal Muscular Atrophy Market, By Disease Type:

Type I
Type II
Type III
Type IV

Global Spinal Muscular Atrophy Market, By Treatment:

Gene Therapy
Drugs

Global Spinal Muscular Atrophy Market, By Age:

Infant
Adult

Global Spinal Muscular Atrophy Market, By Geography:

North America

By Disease Type:

Type I
Type II
Type III
Type IV

By Treatment:

Gene Therapy
Drugs

By Age:

Infant
Adult

By Country:

U.S.
Canada

Latin America

By Disease Type:

Type I
Type II
Type III
Type IV

By Treatment:

Gene Therapy
Drugs

By Age:

Infant
Adult

By Country:

Brazil
Mexico
Argentina
Rest of Latin America

Europe

By Disease Type:

Type I
Type II
Type III
Type IV

By Treatment:

Gene Therapy
Drugs

By Age:

Infant
Adult

By Country:

U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe

Asia Pacific

By Disease Type:

Type I
Type II
Type III
Type IV

By Treatment:

Gene Therapy
Drugs

By Age:

Infant
Adult

By Country:

China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific

Middle East

By Disease Type:

Type I
Type II
Type III
Type IV

By Treatment:

Gene Therapy
Drugs

By Age:

Infant
Adult

By Country:

GCC
Israel
Rest of Middle East

Africa

By Disease Type:

Type I
Type II
Type III
Type IV

By Treatment:

Gene Therapy
Drugs

By Age:

Infant
Adult

By Country:

Central Africa
South Africa
North Africa

Company Profiles

Biogen*

Company Overview
Product Portfolio
Key Highlights
Financial Overview
Market Strategy

Cytokinetics, Inc.
F. Hoffmann-La Roche
Pfizer Inc.
Novartis AG
Ionis Pharmaceuticals, Inc.

“*” marked represents similar segmentation in other categories in the respective section.